Literature DB >> 20405180

Cell death modulation by intravenous immunoglobulin.

Stephan von Gunten1, Hans-Uwe Simon.   

Abstract

The induction of cell death in immune cells by naturally occurring antibodies specific for death receptors may present an important antiinflammatory mechanism of intravenous immunoglobulin (IVIG). Conversely, the protection of tissue cells from death receptor-mediated apoptosis by blocking antibodies is thought to contribute to the beneficial effects of IVIG in certain inflammatory disorders such as toxic epidermal necrolysis, also known as Lyell's syndrome. In this review, we focus on recent insights into the role of functional antibodies against Fas, sialic acid-binding immunoglobulin-like lectin (Siglec)-8, and Siglec-9 receptors in IVIG-mediated cell survival or death effects. In addition, we examine a variety of factors in inflammatory disease that may interplay with these cellular events and influence the therapeutic efficacy or potency of IVIG. These involve activation status of the target cell, cytokine microenvironment, pathogenesis and stage of disease, individual genetic determinants, species characteristics, and batch-to-batch variations of IVIG preparations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20405180     DOI: 10.1007/s10875-010-9411-8

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  9 in total

Review 1.  Multifarious roles of sialic acids in immunity.

Authors:  Ajit Varki; Pascal Gagneux
Journal:  Ann N Y Acad Sci       Date:  2012-04       Impact factor: 5.691

2.  Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.

Authors:  Camilla Jandus; Kayluz Frias Boligan; Obinna Chijioke; He Liu; Meike Dahlhaus; Thomas Démoulins; Christoph Schneider; Marc Wehrli; Robert E Hunger; Gabriela M Baerlocher; Hans-Uwe Simon; Pedro Romero; Christian Münz; Stephan von Gunten
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

3.  Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations.

Authors:  S von Gunten
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 4.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

Review 5.  Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective.

Authors:  Manu Shankar-Hari; Jo Spencer; William A Sewell; Kathryn M Rowan; Mervyn Singer
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

6.  A differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms.

Authors:  Sarah Casulli; Selma Topçu; Lakhdar Fattoum; Stephan von Gunten; Hans-Uwe Simon; Jean-Luc Teillaud; Jagadeesh Bayry; Srini V Kaveri; Carole Elbim
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

7.  IVIG regulates the survival of human but not mouse neutrophils.

Authors:  Christoph Schneider; Simone Wicki; Stefanie Graeter; Tankica M Timcheva; Christian W Keller; Isaak Quast; Danila Leontyev; Iglika K Djoumerska-Alexieva; Fabian Käsermann; Stephan M Jakob; Petya A Dimitrova; Donald R Branch; Richard D Cummings; Jan D Lünemann; Thomas Kaufmann; Hans-Uwe Simon; Stephan von Gunten
Journal:  Sci Rep       Date:  2017-05-02       Impact factor: 4.379

8.  Enhanced Pro-apoptotic Effects of Fe(II)-Modified IVIG on Human Neutrophils.

Authors:  Stefanie Graeter; Christoph Schneider; Daniëlle Verschoor; Sandro von Däniken; Frank Seibold; Nikhil Yawalkar; Peter Villiger; Jordan D Dimitrov; David F Smith; Richard D Cummings; Hans-Uwe Simon; Tchavdar Vassilev; Stephan von Gunten
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

9.  Modulatory Effects of Antibody Replacement Therapy to Innate and Adaptive Immune Cells.

Authors:  Isabella Quinti; Milica Mitrevski
Journal:  Front Immunol       Date:  2017-06-16       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.